The animal and human health platform Labiana is finalising its IPO for mid-June through a capital increase, with the aim of “accelerating growth and improving market positioning through a defined plan of organic and inorganic growth”.
In a statement, Labiana said it has already met with “reference” investors, both in Spain and Europe, and has secured the commitment of the venture capital firm Inveready, which will invest up to four million euros.
Founded in 1958, the company specialises in the manufacture of pharmacological products for veterinary use and has a portfolio of its own medicines with more than fifty products marketed in more than 150 countries and with more than three hundred customers.
The group is now looking to continue to grow “benefiting from positive market trends, growth in the contract development and manufacturing (CDMO) segment, the launch of new proprietary products in both animal and human health and the entry into new markets, as well as improving its profitability through operational leverage and manufacturing process efficiencies, as a result of all the investments made in the production facilities”.
“We are very pleased with the work that has been done since 2013 when the management team took this step forward to take over the group. The IPO represents the result of this first stage and the beginning of a new one,” said the company’s CEO, Manuel Ramos Ortega.
RocaJuntent has advised underwriters JVC Capital, Caixabank, and Gaesco, with a team led by partner Jaime Tarrero, while Gómez-Acebo & Pombo has advised the issuer.
Gómez-Acebo & Pombo team was led by partner Augusto Piñel, along with senior associate Jacobo Palanca Reh, and associates Emiliano Moreno Rodríguez e Irene Carreño Uría.
